We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Onzima Ventures | ONZ | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.25 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.25 | 1.25 |
| Top Posts |
|---|
Posted at 04/4/2017 13:13 by emc01 Hi there,Does anyone have any information about a potential relist date for N4? I know the acquisition is supposed to complete by mid April and the AGM is on the 18th, and presumably there should be an EGM to approve the name change etc – does anyone know any more about that too? Can I also ask how people found out about the share consolidation and placing opportunity? My ONZ shares were bought through Hargreaves Lansdown but there was no info there about it so I didn’t have an opportunity to buy any of the open offer shares. |
Posted at 30/3/2017 11:29 by westmoreland lad Anyone go for placing shares ?Raising a minimum of £1.65m at 7p per share .One for one warrant at 8.5p, 18 month life. As part of the transaction ONZ will acquire the remaining 51% of N4 Pharma . PS -- Nobody inside, ie. all in the public domain. |
Posted at 29/7/2016 11:35 by fido Been a busy morning.Very quickly before I set off, many here say that onz can increase their stake in N4. However there are those who consider that onz are already in breach of their investment policy. Catch you later. Is Onzima Ventures breaching it's investing policy? By Gary Newman | Tuesday 8 March 2016 Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article. I’ve been noticing a lot of chatter on Twitter about a small AIM investing company called Onzima Ventures (ONZ), so I decided to take a closer look to see if all the fuss was justified! This company was previously known as Ultima Networks until October 15 last year when it changed its name, having disposed of all of its operating activities and then raised £750,000, before expenses, by issuing 107.1 million shares at 0.7p. Last week it saw its share price rocket when it announced that it had acquired a 49% stake in a private company called N4 Pharma Limited, via the issue of 24.27 million Onzima shares (locked in for two years) plus £41,000 in cash. On the face of it N4 Pharma looks quite interesting as it is in the biotech industry and reformulates existing drugs using it’s patented Cocrys and Nuvac technology platforms, plus founder Nigel Theobald has over 25 years in the industry. As part of the deal Onzima also agreed to provide a loan facility of £209,000 to develop the business, at an annual rate of 5% and repayable after four years, and there has been much excitement on the chat forums about how great N4 and it’s products are – although it is yet to actually have any product approved or ready for market. The main focus seems to be around a faster-acting alternative to existing Viagra, where the patent ran out in 2013, and there have been boasts about this market being potentially worth $4 billion. With that in mind I find it somewhat strange that N4 Pharma has had to turn to a tiny AIM company like Onzima to secure the funding that it needs, as you’d think that potential investors would be crawling all over it if the product was that good! It is hard to find that much information on N4 Pharma as it is privately listed, although its last accounts up to the end of March 2015 did show that it had trade creditors of over £52,000, with just £5,500 in the bank and net liabilities of nearly £37,000. This might suggest that it wasn’t in great financial shape, having only been set up a couple of years or so ago, yet Onzima has paid the equivalent of around £200,000 in cash and shares for it’s 49% stake. Given the costs often associated with biotech and getting a final drug to market, even if it is only in a new form, I have to wonder how much more cash it is going to need in the future, as well as whether bigger companies are going to just stand aside and allow it to grab a share of the Viagra market, or that of any other major drug for that matter! But what also interests me is whether Onzima is adhering to its investing policy, as set out when it changed it’s name and became an investing company. It raised net proceeds of £650,000 from the equity issue, which amounted to its net cash at the time, and its investing policy states that it will seek to invest a minimum of 75% of its deployable capital in the natural resources sector – an area it’s CEO Gavin Burnell (of Globo infamy) knows well from previous directorships in companies such as Magnolia Petroleum (MAGP), plus a number of current ones. Now I can’t help wondering if that leaves Onzima in breach of its investing policy, given that the money potentially loaned to N4 is no longer available to be invested as stated – although in terms of direct investment in N4 the company hasn’t breached the agreed 25% limit for non-natural resources based interests. Aside from this Onzima also invested £50,000 in fellow AIM investment company Glenwick (GWIK) at 0.1p back in December, and seems to have flipped that in circumstances which raised eyebrows (HERE). Onzima shares are currently trading at around 1.1p to buy and that gives a market cap of nearly £1.5 million, which represents a considerable mark-up to it’s actual asset value (given what it has paid for it’s share of N4 you would have to assume that is the current value of that 49% - although selling it to anyone else might not be easy so that is being generous!). There is also a £4 million debt technically due to the company as a result of the disposal of its previous assets, but any repayment of that will only benefit those holding special deferred shares, via any special dividend, which were issued when the capital was reorganised prior to the equity issue at 0.7p. This could well see further spikes in the future, but I would expect the majority of those to be based more on hype than substance, and therefore consider this company to be extremely high risk and not one for novice investors or small PIs to consider risking their money in. Even more so when I think there is the potential for questions to be raised about a possible breach of it’s investing criteria, plus the past few days are probably the first real chance that those 0.7p placees from back in October have had to offload at a profit, given very thin daily volumes for several months! - See more at: |
Posted at 28/7/2016 15:01 by fido CuFeS2,Not 100% sure of your meaning but if you are saying that Nigel said that he would be looking to float N4 via onz then that is a complete lie because he didn`t say that at all. What he did say was that he was flexible about his options and included onz as one of a number of options. In fact if you were to listen carefully to what Nigel said you would hear him say that a vehicle that could offer him the full £2-3 million would be the best vehicle for N4. As onz does NOT have that kind of money I would say that it actually looks like Nigel WILL NOT be using onz to float. What is actually happening here is that Nigel keeps on dangling the carrot but actually guarantees NOTHING. If a company were to offer him £3 million and a clean route to market then he would jump at it. That company is NOT onz and the day Nigel announced a deal with another vehicle will see the onz suffer a substantial crash as the reality kicks in. I do not believe onz is able to survive without the pull of N4. |
Posted at 28/7/2016 13:47 by cufes2 Nigel owns 16% of ONZ . . . ONZ owns 49% of Nigel’s company N4 Pharma . . . in his presentation Nigel was talking about potentially floating N4 Pharma (edit I meant N4 Pharma and not ONZ) at some point in the future, using ONZ and/or setting up some partnerships for individual drugs . . . but Nigel specifically said . . . "We've tried to set it up with the greatest amount of flexibility so that we can maintain the value for our existing shareholders, us being Onzima and myself" . . . now explain why Nigel is going to compromise ONZ . . . |
Posted at 26/7/2016 17:11 by fido Keya.N4 is the ONLY reason people are here. That is why if N4 fail to sign a deal ONZ will be dead within a few months. If N4 do get a deal and use another vehicle to market ONZ will be dead within a few months. You are suggesting ONZ are a good investment but that view depends entirely om EVERYTHING going to plan and EVERY decision to go ONZ way. Reality is not like that and if they have any setbacks of if say Nigel were to go with an alternative route to market such as the one I will be suggesting then without a shadow of doubt ONZ will be dead within a few months. NOTHING repeat NOTHING is certain in this life but you are expecting people to invest on the basis of everything going to plan. What we have at the moment is fund raising after fund raising with NO production, no revenues and No guarantees. If Nigel were to walk away because maybe another shell offered more investment cash then it would be game over for ONZ and ONZ would join the list of Burnell`s other failures. |
Posted at 24/7/2016 21:02 by bigego Great post before K5000, it upset the nasty man!-------- keya5000 24 Jul'16 - 19:52 - 206 of 228 2 0 thoughts below of an associate who holds an interest in ONZ covers the near term drivers very well. We all know this depends on the success of N4 but the main man has been there and done it before. Good chance we will see history repeat itself. I asked Nigel Theobald why he left his previous company. He replied that he left because he thinks he can do better with n4. That's good enough for me. --------- I think the drivers for the ONZ share price catalysed by N4 are (in a very rough chronological order – although as you know it’s all highly uncertain!): -Further patent filings for other potential drugs that can be reformulated b N4’s platforms (although admittedly these will not be major share price drivers, these announcements will help to paint a picture of the range of revenue streams that N4 could enjoy in the longer term) -Results on sildenafil PoC studies -Securing a major pharma as a partner in bringing a reformulated sildenafil to market. Ideally we’ll see the partner entirely funding the development whilst taking a big portion of future revenue share. This process of seeking a partner for sildenafil was commenced three months ago -Securing a major partner for the Cocrys platform as a whole -Grant funding for Nuvac and/or Nuvec platforms (again staves off equity dilution to N4 (and thus to ONZ), something that private investors love). These two appear slightly behind Cocrys in terms of development -Results on further testing of Nuvac/Nuvec platforms -Securing a major partner to fund the further development of these platforms -Announcement of next major product to be developed on the platforms after sildenafil Beyond these specific catalysts, what I really like about the N4 story is: -Nigel’s track record in the space -Nigel’s belief in the potential of the platforms that he has created (as evinced by his share purchases in placings and on the open market) -The business model (circa £3m in total per reformulation of a particular product, and the short time to market (2.5-3 years); which if successful can result in annual sales for any particular product of many tens of millions of £) -The likely route to market via ONZ. An RTO is the very obvious move here, with ONZ enjoying a bargaining chip via its existing loan note (which will likely be made convertible at the time of RTO, along with the issuance of consideration shares for Nigel and a placing of new shares to fund the next two years of ops). I don’t think this will occur until news of a partnership with a major comes, at which point the RTO can be achieved at a materially higher share price -The obvious takeover target that N4 represents (specifically, by Pfizer, given that sildenafil is N4’s first drug it is reformulating. I picture Pfizer taking out all of N4 and first and foremost using the reformulated sildenafil to simply ‘refresh’ I’m also getting increasingly confident that a second (and potentially third) biopharma investment will be made in the near future. The rationale for this is based on: - our CEO hinting at increasing exposure to the space (in the Year End results); - the creation of the two divisions, asset trading and business development (were only one long term investment to be made and held, I feel that the creation of the B.D. division would have been largely pointless); - our directors not having bought stock on the open market. Inside? So news on this front likewise has the potential to act as a significant share price driver for ONZ. I believe cash burn is currently circa £15k per month, so there’s ample leg room before any fundraise is required. Indeed, it would seem that the Asset Trading division is covering all corporate overheads! |
Posted at 24/7/2016 19:52 by keya5000 thoughts below of an associate who holds an interest in ONZ covers the near term drivers very well. We all know this depends on the success of N4 but the main man has been there and done it before. Good chance we will see history repeat itself.I asked Nigel Theobald why he left his previous company. He replied that he left because he thinks he can do better with n4. That's good enough for me. --------- I think the drivers for the ONZ share price catalysed by N4 are (in a very rough chronological order – although as you know it’s all highly uncertain!): -Further patent filings for other potential drugs that can be reformulated b N4’s platforms (although admittedly these will not be major share price drivers, these announcements will help to paint a picture of the range of revenue streams that N4 could enjoy in the longer term) -Results on sildenafil PoC studies -Securing a major pharma as a partner in bringing a reformulated sildenafil to market. Ideally we’ll see the partner entirely funding the development whilst taking a big portion of future revenue share. This process of seeking a partner for sildenafil was commenced three months ago -Securing a major partner for the Cocrys platform as a whole -Grant funding for Nuvac and/or Nuvec platforms (again staves off equity dilution to N4 (and thus to ONZ), something that private investors love). These two appear slightly behind Cocrys in terms of development -Results on further testing of Nuvac/Nuvec platforms -Securing a major partner to fund the further development of these platforms -Announcement of next major product to be developed on the platforms after sildenafil Beyond these specific catalysts, what I really like about the N4 story is: -Nigel’s track record in the space -Nigel’s belief in the potential of the platforms that he has created (as evinced by his share purchases in placings and on the open market) -The business model (circa £3m in total per reformulation of a particular product, and the short time to market (2.5-3 years); which if successful can result in annual sales for any particular product of many tens of millions of £) -The likely route to market via ONZ. An RTO is the very obvious move here, with ONZ enjoying a bargaining chip via its existing loan note (which will likely be made convertible at the time of RTO, along with the issuance of consideration shares for Nigel and a placing of new shares to fund the next two years of ops). I don’t think this will occur until news of a partnership with a major comes, at which point the RTO can be achieved at a materially higher share price -The obvious takeover target that N4 represents (specifically, by Pfizer, given that sildenafil is N4’s first drug it is reformulating. I picture Pfizer taking out all of N4 and first and foremost using the reformulated sildenafil to simply ‘refresh’ I’m also getting increasingly confident that a second (and potentially third) biopharma investment will be made in the near future. The rationale for this is based on: - our CEO hinting at increasing exposure to the space (in the Year End results); - the creation of the two divisions, asset trading and business development (were only one long term investment to be made and held, I feel that the creation of the B.D. division would have been largely pointless); - our directors not having bought stock on the open market. Inside? So news on this front likewise has the potential to act as a significant share price driver for ONZ. I believe cash burn is currently circa £15k per month, so there’s ample leg room before any fundraise is required. Indeed, it would seem that the Asset Trading division is covering all corporate overheads! |
Posted at 23/7/2016 22:31 by fido PC, absolutely nothing.Whenever I sell its going to be at a loss and that loss is insignificant to me. My shares in UTN/ONZ have been a bottom draw company for me for years and as I said I was not posting on the UTN board for about a year and a half before ONZ. As I have said a great many times, UTN/ONZ are of little interest to me as such but the RAMPING of the stock is. You will almost certainly disagree with me but I have seen so many people lose so much money at the hands of the rampers that I actually find it offensive. Just as I highlighted yesterday you have got people here saying downright lies about the company and what is true is a gross exaggeration of it. Now you might find that acceptable in the interest of making a fast buck but I see it as ripping people off. A lot of what is being said on this and other boards is pure fantasy but it is being portrayed as a cast iron certainty when it most certainly is not. ONZ are a high risk casino stock but is being sold as easy money. If the stock itself wasn`t bad enough you only have to look at the people behind the company to see a history of investors losing their money. To prove the point I will start posting some of the horror stories next week where people have lost everything and it is the same names behind a number of failed companies with ONZ being the latest.If ONZ were to go the same way then the biggest losers would be the hi capital investors who should know the risk but the purpose of all the RAMPING we are seeing is to suck in the herd with the promise of easy money by those who have no conscience about blatant lies whatsoever. To me that is deplorable which is why I have continued to post in an effort to level the playing field, if the ramping were to stop then so would I but of course that`s not going to happen because RAMPING is all part of the process of fleecing new investors. |
Posted at 22/7/2016 14:14 by bigego Strange way to behave when you are meeting someone next week to sell them the idea of taking on N4???------------------ Tweets & replies DaveD @Dav012d 11m11 minutes ago #ONZ There`s that P word again. When I play the lottery I have the "POTENTIAL" to be a millionaire Just the slight problem of the odds. 0 retweets 0 likes DaveD @Dav012d 14m14 minutes ago #ONZ He done it before he will do it again" Not without a big producer saying YES he won`t Anyone want to flip a coin? 0 retweets 0 likes DaveD @Dav012d 16m16 minutes ago #ONZ HIGH RISK casino stock Talk of a scam No deal No drugs No revenue Little investment capital Reliant on the begging bowl. 0 retweets 0 likes Promoted Tweet Money-Short-Cuts @moneyshortcu Brilliant way to check if you had PPI! Promoted 9 retweets 20 likes DaveD @Dav012d 20m20 minutes ago #ONZ Checked up on a RAMPER lie ie ONZ having 1st option over the rest of N4 Just as I thought, it is a complete lie N4 have many options 0 retweets 0 likes DaveD @Dav012d 2h2 hours ago #ONZ Nigel tweeted spread the N4 word These interviews aim to fan the RAMPERS fire and little more. No deal No drugs No money Ramp & Hype 0 retweets 0 likes DaveD @Dav012d 2h2 hours ago #ONZ Promise the world and deliver NOTHING Some would call that a scam 0 retweets 0 likes DaveD @Dav012d 2h2 hours ago #ONZ Same tired old message as in all the other interviews, almost word for word. Nothing new at all. Time to stop talking & do it 0 retweets 0 likes DaveD @Dav012d 4h4 hours ago #ONZ Question How easy is it going to be for ONZ to raise cash when there are city concerns about a scam. Where will N4 be without funding. 0 retweets 0 likes DaveD @Dav012d 4h4 hours ago #ONZ The time-scales are years away In the meantime N4 have not much capital and need 2-3 million ONZ only have the begging bowl NOT GOOD 0 retweets 0 likes DaveD @Dav012d 4h4 hours ago #ONZ Pie in the sky figures like the world is going to stand aside and let N4 take market share. Meanwhile back in the real world....... 0 retweets 0 likes DaveD @Dav012d 4h4 hours ago #ONZ , Justin asked the same tired old questions as he did on his pod cast and got the same tired old answers. Back to sleep. 0 retweets 0 likes DaveD @Dav012d 4h4 hours ago #ONZ Patents are not the same as "working on" so N4 have 1 drug that is 2 years away IFthey get a deal, At the moment they have NOTHING 1 retweet 0 likes DaveD @Dav012d 4h4 hours ago #ONZ RAMPERS said N4 were already working on 10-20 other drugs The interview states they will only file for patents on 8-9 in the next year 0 retweets 0 likes DaveD @Dav012d 4h4 hours ago #ONZ Fact is that Nigel has NO DEAL Very little money Only has ONZ with its begging bowl. Not the best of odds is it. 0 retweets 0 likes DaveD @Dav012d 4h4 hours ago #ONZ Nigel needs another 2-3 million to bring viagra to market. Where`s that money coming from and how`s he doing it without a JV deal. 0 retweets 0 likes Promoted Tweet Funded Solar Panels @GetFundedSol Homeowner? Check if your Postcode Qualifies for Fully Funded Solar Panels. hxxp://www.fundedsol Promoted 20 retweets 48 likes DaveD @Dav012d 5h5 hours ago #ONZ Oh dear how embarrassing for Nigel. On the plus side, a few more of the RAMPERS lies shown for what they are, Same tired old message. 0 retweets 1 like DaveD @Dav012d 6h6 hours ago #ONZ Nigel should walk the walk NOT talk the talk. If its that good then make it good NOT spend all your time at interviews talking about it 0 retweets 0 likes DaveD @Dav012d 6h6 hours ago #ONZ I can remember David Robson spending all his time at interviews talking of multi baggers. His company all but went bust. Talk is cheap 0 retweets 0 likes DaveD @Dav012d 6h6 hours ago #ONZ Lets compare Nigel`s Momentous interview with all the others he`s done and see if anyone can spot the difference other than the date 0 retweets 0 likes |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
